Adocia SA (ADOC.PA)
EUR 6.39
(1.59%)
EUR 6.39
(1.59%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 127 Thousand EUR | -99.2% |
| 2022 | 15.78 Million EUR | -18.26% |
| 2021 | 19.31 Million EUR | 23746.91% |
| 2020 | 81 Thousand EUR | 100.36% |
| 2019 | -22.5 Million EUR | 31.22% |
| 2018 | -32.72 Million EUR | -20.28% |
| 2017 | -27.2 Million EUR | 46.62% |
| 2016 | -50.96 Million EUR | 28.49% |
| 2015 | -71.27 Million EUR | -50.05% |
| 2014 | -47.49 Million EUR | -176.46% |
| 2013 | -17.18 Million EUR | 38.68% |
| 2012 | -28.02 Million EUR | -711.47% |
| 2011 | -3.45 Million EUR | 65.28% |
| 2010 | -9.94 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -3.94 Million EUR | 0.0% |
| 2023 Q3 | 127 Thousand EUR | -99.23% |
| 2023 Q4 | 127 Thousand EUR | 0.0% |
| 2023 Q1 | 16.46 Million EUR | 4.28% |
| 2023 FY | 127 Thousand EUR | -99.2% |
| 2023 Q2 | 16.46 Million EUR | 0.0% |
| 2022 FY | 15.78 Million EUR | -18.26% |
| 2022 Q3 | 15.78 Million EUR | 107.0% |
| 2022 Q4 | 15.78 Million EUR | 0.0% |
| 2022 Q2 | 7.62 Million EUR | 0.01% |
| 2022 Q1 | 7.62 Million EUR | -60.52% |
| 2021 Q3 | 19.31 Million EUR | 159.24% |
| 2021 Q4 | 19.31 Million EUR | 0.0% |
| 2021 Q1 | 7.45 Million EUR | 9098.77% |
| 2021 FY | 19.31 Million EUR | 23746.91% |
| 2021 Q2 | 7.45 Million EUR | 0.0% |
| 2020 Q2 | -14.9 Million EUR | -0.01% |
| 2020 Q1 | -14.9 Million EUR | 33.79% |
| 2020 Q3 | 80 Thousand EUR | 100.54% |
| 2020 Q4 | 81 Thousand EUR | 1.25% |
| 2020 FY | 81 Thousand EUR | 100.36% |
| 2019 Q2 | -12.6 Million EUR | 0.0% |
| 2019 Q4 | -22.5 Million EUR | 0.0% |
| 2019 FY | -22.5 Million EUR | 31.22% |
| 2019 Q1 | -12.6 Million EUR | 61.49% |
| 2019 Q3 | -22.5 Million EUR | -78.6% |
| 2018 Q3 | -32.72 Million EUR | 31.84% |
| 2018 FY | -32.72 Million EUR | -20.28% |
| 2018 Q4 | -32.72 Million EUR | 0.0% |
| 2018 Q2 | -48 Million EUR | -0.34% |
| 2018 Q1 | -47.84 Million EUR | -75.85% |
| 2017 Q1 | -45.27 Million EUR | 11.16% |
| 2017 Q2 | -45.27 Million EUR | 0.0% |
| 2017 Q3 | -27.2 Million EUR | 39.91% |
| 2017 Q4 | -27.2 Million EUR | -0.0% |
| 2017 FY | -27.2 Million EUR | 46.62% |
| 2016 Q2 | -54.71 Million EUR | -0.14% |
| 2016 FY | -50.96 Million EUR | 28.49% |
| 2016 Q1 | -54.63 Million EUR | 23.34% |
| 2016 Q3 | -50.96 Million EUR | 6.85% |
| 2016 Q4 | -50.96 Million EUR | 0.0% |
| 2015 Q3 | -71.22 Million EUR | 0.36% |
| 2015 Q2 | -71.48 Million EUR | -0.12% |
| 2015 FY | -71.27 Million EUR | -50.05% |
| 2015 Q1 | -71.39 Million EUR | -50.31% |
| 2015 Q4 | -71.27 Million EUR | -0.06% |
| 2014 Q2 | -13.67 Million EUR | -0.98% |
| 2014 Q3 | -47.49 Million EUR | -247.44% |
| 2014 Q4 | -47.49 Million EUR | 0.0% |
| 2014 Q1 | -13.53 Million EUR | 21.2% |
| 2014 FY | -47.49 Million EUR | -176.46% |
| 2013 Q1 | -20.72 Million EUR | 26.02% |
| 2013 Q4 | -17.18 Million EUR | 0.0% |
| 2013 Q2 | -20.72 Million EUR | 0.0% |
| 2013 Q3 | -17.18 Million EUR | 17.11% |
| 2013 FY | -17.18 Million EUR | 38.68% |
| 2012 Q3 | -30.46 Million EUR | 9.62% |
| 2012 Q4 | -28.02 Million EUR | 8.02% |
| 2012 FY | -28.02 Million EUR | -711.47% |
| 2012 Q2 | -33.7 Million EUR | 0.0% |
| 2011 FY | -3.45 Million EUR | 65.28% |
| 2011 Q4 | -3.45 Million EUR | 0.0% |
| 2010 FY | -9.94 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | 117.787% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 100.065% |
| Aelis Farma SA | -16.19 Million EUR | 100.784% |
| Biophytis S.A. | 2.7 Million EUR | 95.302% |
| Advicenne S.A. | 12.17 Million EUR | 98.957% |
| genOway Société anonyme | 2.97 Million EUR | 95.728% |
| IntegraGen SA | -709.74 Thousand EUR | 117.894% |
| Medesis Pharma S.A. | 1.15 Million EUR | 89.035% |
| Neovacs S.A. | -237.08 Thousand EUR | 153.567% |
| NFL Biosciences SA | -2.27 Million EUR | 105.58% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 97.085% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | 115.291% |
| Sensorion SA | 1.37 Million EUR | 90.785% |
| Theranexus Société Anonyme | 2.44 Million EUR | 94.804% |
| TME Pharma N.V. | -1.07 Million EUR | 111.77% |
| Valbiotis SA | -18.13 Million EUR | 100.7% |
| TheraVet SA | 12.78 Thousand EUR | -893.352% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | 94.174% |
| argenx SE | -1.83 Billion EUR | 100.007% |
| BioSenic S.A. | 28.04 Million EUR | 99.547% |
| Celyad Oncology SA | -6.1 Million EUR | 102.081% |
| DBV Technologies S.A. | -114.95 Million USD | 100.11% |
| Galapagos NV | -157.2 Million EUR | 100.081% |
| Genfit S.A. | -7.61 Million EUR | 101.669% |
| GeNeuro SA | 5.91 Million EUR | 97.851% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 100.506% |
| Innate Pharma S.A. | -30.71 Million EUR | 100.414% |
| Inventiva S.A. | 10.48 Million EUR | 98.789% |
| MaaT Pharma SA | -10.2 Million EUR | 101.244% |
| MedinCell S.A. | 39.5 Million EUR | 99.678% |
| Nanobiotix S.A. | -24.71 Million EUR | 100.514% |
| Onward Medical N.V. | -12.89 Million EUR | 100.985% |
| Oryzon Genomics S.A. | 1.43 Million EUR | 91.121% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 99.532% |
| Oxurion NV | 10.71 Million EUR | 98.814% |
| Pharming Group N.V. | 99.4 Million EUR | 99.872% |
| Poxel S.A. | 44.55 Million EUR | 99.715% |
| GenSight Biologics S.A. | 16.29 Million EUR | 99.221% |
| Transgene SA | -14.4 Million EUR | 100.881% |
| Financière de Tubize SA | 78.62 Million EUR | 99.838% |
| UCB SA | 2.17 Billion EUR | 99.994% |
| Valneva SE | 82.73 Million EUR | 99.846% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 100.686% |